Live Breaking News & Updates on Kidney Cancer Program

Stay updated with breaking news from Kidney cancer program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Study reveals unexpected mechanism of drug resistance in kidney cancer

For nearly two decades, how kidney cancer becomes resistant to rapalog drugs has baffled the scientific community. Now a study by researchers at UT Southwestern Medical Center s Kidney Cancer Program sheds light. Published in the Proceedings of the National Academy of Sciences, the study "Unconventional Mechanism of Action and Resistance to Rapalogs in Renal Cancer" provides evidence for an unanticipated role for nontumor cells in mediating the therapeutic effects of rapalogs in kidney cancer. ....

Juan-yang , James-brugarolas , Brugarolas-lab , Kidney-cancer-program , Proceedings-of-the-national-academy-sciences , Division-of-hematology , Ut-southwestern-medical-center-kidney-cancer-program , Southwestern-medical-center , Haroldc-simmons-comprehensive-cancer-center , Southwestern-medical , Medical-center , National-academy

Study reveals unexpected mechanism of drug resista

For nearly two decades, how kidney cancer becomes resistant to rapalog drugs has baffled the scientific community. Now a study by researchers at UT Southwe ....

Dallas , Texas , United-states , Jiwoong-kim , Alana-christie , James-brugarolas , Robert-lewis-kirby , Jerry-knight-rymer , Vanina-toffessi-tcheuyap , Arijit-mal , Annette-brannon-rymer , Payal-kapur

Study reveals unexpected mechanism of drug resista

For nearly two decades, how kidney cancer becomes resistant to rapalog drugs has baffled the scientific community. Now a study by researchers at UT Southwe ....

Dallas , Texas , United-states , Ramesh-butti , Mylinh-nguyen , Payal-kapur , Annette-brannon-rymer , Vanina-toffessi-tcheuyap , Arijit-mal , Jerry-knight-rymer , Robert-lewis-kirby , James-brugarolas

Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC

Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC. ....

Massachusetts , United-states , Boston , Dana-farber-cancer-institute , America , Toni-choueiri , Nancy-kohlberg , Memorial-sloan-kettering-cancer-center , International-metastatic , Database-consortium , Professor-of-medicine-at-harvard-medical-school , Lank-center

DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC

The small molecule inhibitor DFF332 elicited clinical activity and had a tolerable safety profile in patients with advanced clear cell renal cell carcinoma. ....

California , United-states , Sumanta-kumar-pal , Bladder-cancer-disease-team , Kidney-cancer-program , Database-consortium , International-metastatic , Medical-oncology , Therapeutics-research , Hope-comprehensive-cancer-center ,